Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

(2019) Vicky Makker et al.   LANCET ONCOLOGY

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Hyun Cheol Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3

(2019) Youn Jin Choi et al.   CLINICAL CANCER RESEARCH

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer

(2018) Erminia Massarelli et al.   JAMA Oncology

Cervical Adenocarcinoma Has a Poorer Prognosis and a Higher Propensity for Distant Recurrence Than Squamous Cell Carcinoma

(2017) Eun Jung Jung et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Current progress in immunotherapy for pancreatic cancer

(2016) Kelly Foley et al.   CANCER LETTERS

Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells

(2016) Y. W. Choi et al.   CLINICAL CANCER RESEARCH

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response

(2016) M. I. E. van Poelgeest et al.   CLINICAL CANCER RESEARCH

Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix

(2016) A Marijne Heeren et al.   MODERN PATHOLOGY

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

(2015) Cornelia L Trimble et al.   LANCET

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

(2015) A. Ribas   Cancer Discovery

Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFN 

(2014) R.-S. Soong et al.   CLINICAL CANCER RESEARCH

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients

(2014) Tae Jin Kim et al.   Nature Communications

Prevalence and type distribution of human papillomavirus in cervical adenocarcinoma in Korean women

(2013) Jong-Sup Park et al.   GYNECOLOGIC ONCOLOGY

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man

(2012) E. Barnes et al.   Science Translational Medicine

Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy

(2011) Jean-Luc Brun et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3

(2009) Cornelia L. Trimble et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation

(2009) Sang Hwan Seo et al.   VACCINE